[COVID-19 in transplant recipients: Multicentric report of Mexican experience].

IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS

Archivos de cardiologia de Mexico Pub Date : 2023-09-05 DOI:10.24875/ACM.21000113

Mónica Sánchez-Cárdenas, Enzo Vásquez-Jiménez, Ricardo I Velázquez-Silva, Mario Vilatobá-Chapa, Benjamín Gómez-Navarro, Lucio O Sánchez-Macías, José M Rodríguez-Chagolla, Ignacio García-Juárez, Severo M Abraham-Mancilla, Luis E Morales-Buenrostro, Idalia Parra-Ávila, César Flores-Gama

{"title":"[COVID-19 in transplant recipients: Multicentric report of Mexican experience].","authors":"Mónica Sánchez-Cárdenas, Enzo Vásquez-Jiménez, Ricardo I Velázquez-Silva, Mario Vilatobá-Chapa, Benjamín Gómez-Navarro, Lucio O Sánchez-Macías, José M Rodríguez-Chagolla, Ignacio García-Juárez, Severo M Abraham-Mancilla, Luis E Morales-Buenrostro, Idalia Parra-Ávila, César Flores-Gama","doi":"10.24875/ACM.21000113","DOIUrl":null,"url":null,"abstract":"Background: Solid Organ Transplant recipients (SOTR) appear to be at particular high risk for critical COVID-19 due to immunosuppressive drugs and comorbidities. We report the first description of clinical course and short-term outcomes of kidney and liver transplant recipients with confirmed COVID-19 in Mexico. The objective of this paper was evaluate the clinical course of transplant patients with COVID-19 infection.Material and methods: We retrospectively evaluated SOTR (kidney and liver) over 18 years of age with confirmed diagnosis of COVID-19 from tertiary care centers in Mexico.Results: Data from 45 kidney transplant recipients were recorded. Median (IQR) age was 43 (IQR 25-70) years. Admission to hospital was required in 37 (75.5 %) patients, of which 8 (16.3%) were hospitalized at Intensive Care Unit (ICU). Acute kidney injury (AKI) stage was documented in 33 (67%) patients. The time of hospitalization was 8 (IQR 6-12) days. Six patients died (12.2%). Additionally, data from 10 liver transplant recipients were included. During their evolution, 5 / 10 required hospital admission and there were no deaths in this group.Conclusions: Transplant recipients show a higher fatality rate and complications from SARS-CoV-2 infection; more studies are needed to identify prognostic factors and effective anti-SARS-CoV-2 therapies.","PeriodicalId":8360,"journal":{"name":"Archivos de cardiologia de Mexico","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivos de cardiologia de Mexico","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24875/ACM.21000113","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Solid Organ Transplant recipients (SOTR) appear to be at particular high risk for critical COVID-19 due to immunosuppressive drugs and comorbidities. We report the first description of clinical course and short-term outcomes of kidney and liver transplant recipients with confirmed COVID-19 in Mexico. The objective of this paper was evaluate the clinical course of transplant patients with COVID-19 infection.

Material and methods: We retrospectively evaluated SOTR (kidney and liver) over 18 years of age with confirmed diagnosis of COVID-19 from tertiary care centers in Mexico.

Results: Data from 45 kidney transplant recipients were recorded. Median (IQR) age was 43 (IQR 25-70) years. Admission to hospital was required in 37 (75.5 %) patients, of which 8 (16.3%) were hospitalized at Intensive Care Unit (ICU). Acute kidney injury (AKI) stage was documented in 33 (67%) patients. The time of hospitalization was 8 (IQR 6-12) days. Six patients died (12.2%). Additionally, data from 10 liver transplant recipients were included. During their evolution, 5 / 10 required hospital admission and there were no deaths in this group.

Conclusions: Transplant recipients show a higher fatality rate and complications from SARS-CoV-2 infection; more studies are needed to identify prognostic factors and effective anti-SARS-CoV-2 therapies.

查看原文本刊更多论文

[移植受者中的 COVID-19：墨西哥经验的多中心报告]。

背景：由于免疫抑制药物和合并症的影响，实体器官移植受者（SOTR）似乎是COVID-19危重症的高危人群。我们首次报道了墨西哥确诊 COVID-19 的肾移植和肝移植受者的临床过程和短期疗效。本文旨在评估感染 COVID-19 的移植患者的临床过程：我们对墨西哥三级医疗中心确诊感染 COVID-19 的 18 岁以上 SOTR（肾脏和肝脏）患者进行了回顾性评估：记录了 45 名肾移植受者的数据。中位（IQR）年龄为 43（IQR 25-70）岁。37名患者（75.5%）需要入院治疗，其中8名患者（16.3%）在重症监护室（ICU）住院治疗。33名（67%）患者的急性肾损伤（AKI）阶段有记录。住院时间为 8 天（IQR 6-12）。六名患者死亡（12.2%）。此外，还包括 10 名肝移植受者的数据。结论：移植受者的死亡率较高：移植受者感染 SARS-CoV-2 后死亡率和并发症较高；需要进行更多的研究，以确定预后因素和有效的抗 SARS-CoV-2 疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Archivos de cardiologia de Mexico Medicine-Cardiology and Cardiovascular Medicine

CiteScore

0.80

自引率

20.00%

发文量

176

审稿时长

18 weeks